Australia Further Delays Cutback In IV Chemo Coverage
This article was originally published in PharmAsia News
Executive Summary
Australia's Health Ministry has decided to extend the Sept. 1 effective date for cutbacks in federal support for intravenous chemotherapy drugs. The delay is the third for the plan to cover only the amount used by a patient for a specific treatment rather than covering the cost of a full vial of the drug. The change was to have taken effect July 1 and then was delayed until Sept. 1, but Minister Nicola Roxon said the effective date would be sometime later, on a date yet to be selected. (Click here for more
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.